The cash will be spread across four years to fund development of the anti-TL1A antibody duvakitug.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
The cash will be spread across four years to fund development of the anti-TL1A antibody duvakitug.